Treatment of Idiopathic Chronic Pancreatitis (ICP) with ivacaftor in a Cystic Fibrosis (CF) carrier who also had a second inherited risk factor for pancreatitis called Methylmalonic Acidemia
Description of children who changed diagnosis from indeterminate newborn screening to cystic fibrosis
Outcomes and endpoints reported in studies of pulmonary exacerbations in people with cystic fibrosis (CF): a systematic review
Prevalence, management and outcome of Italian infants with cystic fibrosis screening positive inconclusive diagnosis
Adjusting the dose of triple therapy (Elexacaftor/Tezacaftor/Ivacaftor) to reduce mental health side effects
Inflammation and infection change what mucus is made of, how much gets made, and how much it can dissolve
